Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences

Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, March 2, 2021
Information
Tags: 
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Medicine, Clinical medicine, Virotherapy, Gene delivery, Genetic engineering, Biotechnology, Oncolytic virus, Transgene, Virus, Viral vector, Immunotherapy
Geotags: 
France, Europe
⚠generated by AI ↴
Summary
Key Points: 
  • Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
  • With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual.
  • The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.


Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that members of Transgene’s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences:

  • ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4:



    Éric Quéméneur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session 'Where next with Oncolytics' about Antibody armed oncolytic viruses (ID 42)

    Date & Time: March 3rd at 4.20pm (CET)
  • Royal Society Meeting on 'Immuno-oncology: How to get the immune system to beat cancer' which will take place March 24-25:



    This Royal Society meeting will explore immuno-oncology therapies - both current and recent technologies. Eric Quéméneur will participate in the immuno-oncology breakthroughs session.

    Date & Time: March 24th at 3.50pm (GMT)
  • 4th Annual European Neoantigen Summit which will take place April 20-22:



    Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines, will be speaking about TG4050: Viral immunotherapy meets AI technology

    Date & Time: April 22nd at 1pm (CET)

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.

Additional information about Transgene is available at: www.transgene.fr // Follow us on Twitter: @TransgeneSA

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Copyright: 
Copyright Business Wire 2021